SKYE BIOSCIENCE INC SKYE 深 沪
等待开盘 09-24 09:30:00 美东时间
1.80
+0.090
+5.26%
华盛通- 最 高1.9499
- 今 开1.74
- 成交量 21.79万股
- 最 低 1.60
- 昨 收 1.71
- 总市值 796.98万
- 52周最高 18.40
- 市盈率 静 --
- 换手率 4.92%
- 52周最低 1.50
- 委 比 -99.01%
- 总股本 442.77万
- 历史最高 141.1784
- 量 比 2.27
- 振 幅 20.46%
- 历史最低 1.60
- 每 手 1
- 风险率 5.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
Skye Bioscience, Inc. (NASDAQ:SKYE) shares rose 6.20% in after-hours trading Tuesday after the company entered into an equity purchase agreement with an affiliate of Redmile Group. The stock closed Tuesday’s regular session down 7.14% at $2.02. It then rose 6.20% to $2.14 in after-hours trading. Sky...
08-26 14:07
Skye Bioscience To Acquire Redx Pharma; Combined Company To Operate As Fibrx Therapeutics With $125M Financing
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, with an open U.S. IND, FDA ...
08-14 21:36
Skye Bioscience Says Cohort Review Committee Unanimously Approves Opening Second Cohort Of CBeyond Part C Expansion Study
Skye Bioscience, Inc. (NASDAQ:SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee
05-20 19:06
Skye Bioscience Treats First Patient In Part C Expansion Study Of CBeyond Phase 2a Trial To Characterize Safety And PK At Exposures To Challenge Peripheral Restriction Of Nimacimab Through IV Administration Over 16 Weeks Of Treatment
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, has treated the first patient in its
04-02 19:12
Skye Bioscience shares are trading lower after the company reported a Q4 EPS miss.
Skye Bioscience shares are trading lower after the company reported a Q4 EPS mi...
03-12 00:12
Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 117.65% and reporting a rise in revenue.
03-11 17:57
Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate
Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 21.21 percent. This is a 50 percent decrease over losses of $(0.24) per share from
03-11 04:02
Earnings Scheduled For March 10, 2026
Companies Reporting Before The Bell • Ultralife (NASDAQ:ULBI) is likely to repo...
03-10 19:11
A Peek at Skye Bioscience's Future Earnings
Skye Bioscience (NASDAQ:SKYE) is set to give its latest quarterly earnings repo...
03-10 01:02
10 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Icecure Medical (NASDAQ:ICCM) shares moved upwards by 17.7% to $0.68 d...
03-02 20:05
